Download Protocol

Sermorelin

Sermorelin helps the body release its own growth hormone naturally. It supports healthy recovery, deeper sleep, and balanced energy. It’s used in research exploring ways to encourage natural hormone function without overstimulation.

Description

• Sermorelin is a synthetic peptide composed of the first 29 amino acids of growth hormone–releasing hormone (GHRH).
• It stimulates the pituitary to release endogenous growth hormone (GH) naturally and rhythmically.
• Used in research on GH deficiency, aging, and recovery biology.

How It Works

• Activates GHRH receptors on pituitary somatotrophs to trigger GH pulses.
• Encourages physiological GH and IGF-1 production.
• Can be paired with GHRP analogs such as Ipamorelin for synergistic response.

Documented Effects

• Increases GH and IGF-1 secretion in animal and early human studies.
• Improves sleep quality and metabolic recovery markers.
• Preserves normal feedback regulation of GH axis.

Theoretical Effects

• Potential for endocrine restoration, lean mass preservation, and metabolic optimization research.

Pharmacokinetics

• Half-life: approximately 10–20 minutes after injection.
• Time to peak concentration: around 5–15 minutes post subcutaneous injection.
• Steady-state: not maintained; transient GH pulses are triggered after each administration.

Duration of Effects

• Stimulated GH release occurs within minutes and returns to baseline in 2–3 hours.
• Downstream IGF-1 elevation may persist for up to 24 hours.
• Regular nightly dosing supports consistent GH rhythm restoration over several weeks.

Reconstitution

• Use only bacteriostatic water to reconstitute the lyophilized powder.
• Example vial: 10 mg of Sermorelin
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; do not shake.
• Refrigerate reconstituted solution (2–8 °C). Use within ~25 days for best stability.

Injectable Dosage Overview (Research Use)

Typical Starting Dose

• 100–200 mcg subcutaneous (SC) once daily before sleep.
• Start at 100 mcg to gauge GH pulse response.

Common Research Range

• 200–500 mcg SC daily, often paired with a GHRP for stronger GH amplitude.
• Evening dosing aligns with natural GH peaks.

Maximum Research Range

• Up to 1 mg SC daily under observation; higher exposure yields little added benefit.

Standard Cycle Length

• 8–12 weeks on → 2–4 weeks off for reassessment of GH axis function.

Clinical Notes

• Injected subcutaneously 1–2 hours before sleep to mimic physiological GH timing.
• No tapering required; GH levels return naturally after discontinuation.
• May be combined cautiously with GHRPs like Ipamorelin but avoid concurrent GH use.
• Stable for about 25 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Possible mild flushing, headache, or tingling due to GH release.
• Maintain sterile technique; confirm compound purity.
• Research compound only; not for therapeutic human use.